drug screening – mycolab.ai

From Mushrooms to Molecules: Exploring Depsidones in Ganoderma lucidum for Antioxidant and Anticancer Applications

mycolabadmin

Researchers studied a medicinal mushroom called Ganoderma lucidum to identify compounds that could fight cancer. They found nine rare compounds called depsidones that showed promise against different types of cancer cells, including liver, colon, breast, and lung cancer. The compounds were shown to work by binding to cancer-related proteins, suggesting they could be developed into new cancer treatments.

Vaping danger: A hidden threat among Malaysia’s youth

mycolabadmin

A 15-year-old student in Malaysia was hospitalized after vaping a product labeled as having a magic mushroom flavor. Testing revealed the vape actually contained MDMB-4en-PINACA, a highly potent synthetic cannabinoid that is 100-200 times stronger than natural cannabis. This case highlights the danger of unregulated vaping products being mixed with illegal substances that can cause serious health effects including seizures, heart problems, and organ damage. Doctors and the public need to be aware of these hidden threats in vaping products.

A human-relevant alternative infection model for mucormycosis using the silkworm Bombyx mori

mycolabadmin

Researchers developed a silkworm-based model to study mucormycosis, a deadly fungal infection. The model reproduces the same disease patterns and risk factors seen in humans, including effects of steroids and iron levels. Importantly, it successfully predicted how well antifungal drugs work against the infection, offering a faster and more ethical alternative to mammal testing for developing new treatments.

Miniaturized high-throughput conversion of fungal strain collections into chemically characterized extract libraries for antimicrobial discovery

mycolabadmin

Scientists developed a fast, automated method called FLECS-96 to screen hundreds of fungal species for antimicrobial compounds in a small 96-well plate format. The method combines fungal culture, chemical extraction, and analysis to identify promising candidates against resistant bacteria like Staphylococcus aureus. The team successfully identified two bioactive compounds from the fungi tested. This innovation could significantly speed up the discovery of new antibiotics to combat antibiotic-resistant infections.

Marine-derived Acremonium strain prioritization using untargeted metabolomics approach for the identification of cytotoxic cyclic depsipeptides

mycolabadmin

Researchers studied six fungal strains from Arctic driftwood to find cancer-fighting compounds. Using advanced chemical analysis methods, they identified one strain that was particularly good at killing cancer cells in the lab. From this strain, they isolated five related compounds called depsipeptides that showed strong activity against multiple types of cancer cells. This discovery highlights how fungi from extreme environments like the Arctic could be valuable sources for developing new cancer treatments.

New Positive TRPC6 Modulator Penetrates Blood–Brain Barrier, Eliminates Synaptic Deficiency and Restores Memory Deficit in 5xFAD Mice

mycolabadmin

Researchers developed a new drug candidate called C20 that activates TRPC6 proteins in the brain. In studies with Alzheimer’s disease mouse models, C20 protected nerve connections from damage, restored memory function, and successfully crossed the blood-brain barrier. The compound shows promise as a potential treatment for Alzheimer’s disease by strengthening the connections between brain cells that are damaged in the disease.

A human-relevant alternative infection model for mucormycosis using the silkworm Bombyx mori

mycolabadmin

Scientists developed a new way to test antifungal drugs using silkworms instead of expensive and ethically problematic mammal studies. They infected silkworms with mucormycosis-causing fungi and found that the infections behaved similarly to human cases, especially when they simulated human risk factors like steroid use and iron overload. The silkworm model successfully demonstrated that existing antifungal drugs work, while also revealing differences in fungal virulence that were linked to specific surface proteins.

Research Keyword: drug screening

From Mushrooms to Molecules: Exploring Depsidones in Ganoderma lucidum for Antioxidant and Anticancer Applications

Vaping danger: A hidden threat among Malaysia’s youth

A human-relevant alternative infection model for mucormycosis using the silkworm Bombyx mori

Miniaturized high-throughput conversion of fungal strain collections into chemically characterized extract libraries for antimicrobial discovery

Marine-derived Acremonium strain prioritization using untargeted metabolomics approach for the identification of cytotoxic cyclic depsipeptides

New Positive TRPC6 Modulator Penetrates Blood–Brain Barrier, Eliminates Synaptic Deficiency and Restores Memory Deficit in 5xFAD Mice

A human-relevant alternative infection model for mucormycosis using the silkworm Bombyx mori